Could reduced dosing maintain more people on antiretrovirals after the sudden cuts in USAID funding? A crisis response

Antiretroviral therapy shortages caused by sudden and severe cuts in USAID and PEPFAR have focused attention on strategies to extend antiretroviral supplies and mitigate this crisis. Efficacy data are now available from seven randomized controlled intermittent triple antiretroviral therapy trials. For countries with urgent drug shortages, this evidence supports intermittent dosing 4-5 days-per-week to extend antiretroviral supplies, with clinical benefits for people living with HIV and continued population benefits of minimizing HIV transmission.